The human microbiome refers to the group of microorganisms such as bacteria, archaea, and fungi that reside on skin layers, in saliva, conjunctiva, oral mucosa and the gastrointestinal tract (GIT). These microorganisms perform tasks which are beneficial for the human host in maintaining health. In microbiome therapeutics: probiotics, prebiotics and synbiotics play a vital role in diagnosis, prevention, and treatment of various disease conditions. Probiotics are microorganisms such as bacteria, yeasts that provide health benefits when consumed. Prebiotics are non-digestible carbohydrate that helps in growth of microbes that are present in the body. Furthermore, combination of probiotics and prebiotics are referred to as synbiotics. The most beneficial factor for microbiome therapeutics is that they do not cause any side effects unlike the drug molecules as they are already present within the body. As a result, they are helpful in treating various disease indications such as Crohn’s disease and irritable bowel syndrome conditions that do not have any proper treatment.
Factors driving growth of the global microbiome therapeutics market are rise in digestive disorders, and increasing incidence of drug-related side effects. In addition, high amount of funding for biological drug development studies and collaboration between major players in the global microbiome market are major factors contributing to growth of global microbiome therapeutics market.
However, high cost of equipment and machinery, and complex processes to develop and extract the bacteria in the laboratory are restraining growth of the global microbiome therapeutics market. In addition, factors such as heat sensitiveness displayed by the microbiomes, and lack of proper regulations are hindering growth of the global microbiome therapeutics market.
Do Inquiry About Report Here: https://marketresearch.biz/report/microbiome-therapeutics-market/#inquiry
The global microbiome therapeutics market report has been segmented on the basis of product type, distribution channel, application area, and region. On the basis of region, the global microbiome therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America market is expected to dominate the global microbiome therapeutics market in terms of revenue share, owing to rise in consumption in of dietary supplements. Moreover, highly established research facility for the development of novel therapeutics, presence of health-conscious population, and rising healthcare expenditure are the major factors for dominance of the region. Europe market is expected to account for second largest market share contribution to the global microbiome therapeutics market, followed by Asia Pacific market. Markets in emerging economies in the Asia Pacific such as Japan and China are anticipated to expand at the highest CAGR of X.X% over the forecast period, due to high amount of biological research initiatives in national institutes, increasing economic stability, and growing awareness among physicians regarding novel therapeutics.
Key players in the global microbiome therapeutics market include, Johnson and Johnson, AB-Biotics, Vedanta Biosciences, AbbVie Inc., Dannon, Yakult, Bayer, Ganeden, Sigma-Tau Pharmaceuticals and Pfizer Inc.
Prudour Pvt. Ltd. ( https://marketresearch.biz) is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge. Prudour Pvt. Ltd. offers services such as data mining, information management, and revenue enhancement solutions and suggestions.